Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance

Analyst Jason Butler of JMP Securities maintained a Buy rating on Cormedix (CRMD – Research Report), retaining the price target of $19.00.

Jason Butler has given his Buy rating due to a combination of factors that indicate a positive outlook for Cormedix. Despite recent stock pressure, Butler remains confident in the company’s ability to commence large dialysis organization (LDO) orders this quarter, which is expected to significantly boost sales. The company’s financial performance in 4Q24, including $31 million in DefenCath sales and achieving profitability with a net income of $13.5 million, supports this optimism.
Furthermore, Cormedix’s management has provided guidance for 1H25 sales between $50-60 million, reflecting stable customer demand. The company is also making strategic advancements, such as expanding DefenCath’s use in hospitals and pursuing new clinical objectives, which could drive future growth. These factors, combined with ongoing partnerships and marketing efforts, underpin Butler’s Buy rating, suggesting substantial upside potential for investors.